Another FDA Rejection for Alimera Sciences Eye Drug

Shares of US ophthalmic drug developer Alimera Sciences (Nasdaq: ALIM) plunged nearly 73% to $2 on Friday, when the company revealed that it has received a complete response letter (CRL) from the US Food and Drug Administration in response to the New Drug Application for Iluvien (fluocinolone acetonide intravitreal insert) for the treatment of diabetic macular edema (DME) associated with diabetic retinopathy.

Back to news